Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.33 |
| ▸ | FPR1 | P21462 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323051 | 1.00 | CNR2 (0.35) | CNR2CNR1HTTMAPTSMN1; SMN2 | |
| SCHEMBL12122067 | 0.89 | ELANE (0.35) | NTRK1BIRC2 | |
| SCHEMBL12124006 | 0.89 | BIRC2 (0.35) | CNR2CNR1HTTMAPTSMN1; SMN2 | |
| SCHEMBL380276 | 0.89 | ELANE (0.35) | NTRK1BIRC2 | |
| SCHEMBL380277 | 0.89 | ELANE (0.35) | NTRK1BIRC2 | |
| SCHEMBL12122006 | 0.88 | HTT (0.38) | CNR2CNR1HTTMAPTSMN1; SMN2 | |
| SCHEMBL1323603 | 0.88 | HTT (0.38) | CNR2CNR1HTTMAPTSMN1; SMN2 | |
| SCHEMBL12124290 | 0.87 | CNR1 (0.37) | CNR2CNR1NTRK1BIRC2XIAP | |
| SCHEMBL1324375 | 0.86 | ELANE (0.37) | NTRK1ROCK2 | |
| SCHEMBL381915 | 0.86 | ELANE (0.40) | BIRC2XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | claimed |
| CN-101595093-A | Organic compound | NOVARTIS AG (CH) | 2009-12-02 | — | — | CN | claimed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048571-A1 | Organic Compounds | XIAP, BAX, MCL1 | CNR2 4877/4885CNR1 4851/4885HTT 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.